Hikma announces positive start to 2019 and reiterates guidance

London, 17 May 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical group, will hold its Annual General Meeting today and provide an update on recent trading.

Press Release Corporate 17 May 2019

text 1

Siggi Olafsson, Hikma’s CEO, said: “We are pleased to be holding our Annual General Meeting today, which will include a review of the Group’s performance in 2018.  We delivered strong growth in revenue and profitability last year, while making significant strategic progress. We have been building on this momentum and 2019 is off to a good start.  Across our three businesses, we are driving good demand for our broad product portfolio and recent product launches. We continue to strengthen our capabilities, pipeline and business operations, whilst maintaining our focus on cost reduction.  I am pleased to reiterate our full year guidance for 2019 and we remain confident in the outlook for the Group and our ability to deliver long-term, sustainable growth.”


Our global Injectables business is performing well.  In the US, strong demand for our large and diversified portfolio is more than offsetting increased competition.  Further demand is being driven by recent product launches, including three products launched in the year to date.  Our Injectables businesses in MENA and Europe are on track to deliver good growth this year, particularly in our top MENA markets.

We continue to expect global Injectables revenue to be in the range of $850 million to $900 million in 2019.  We expect revenue growth from new product launches and good demand for our in-market portfolio to more than offset continued price erosion and an easing in demand for products on shortage.  We expect core operating margin to be in the range of 35% to 38%.


The Generics business has also had a strong start to the year, in line with our expectations.  We have delivered good revenue growth, benefiting from our more differentiated product portfolio. Our strengthened commercial and operational capabilities are enabling us to enhance our customer relationships and drive higher volumes.

We reiterate our guidance for Generics revenue in the range of $650 million to $700 million in 2019.  This reflects our expectation for increased competition on our marketed portfolio, which we expect to partially offset with market share gains and new product launches.  We expect our focus on cost reduction and operational efficiencies to enable us to achieve a core operating margin in the mid-teens.


Our Branded business is delivering good growth, with strong demand in some of our key markets.   As in 2018, we expect a stronger second half, reflecting the usual seasonality of this business.  We continue to expect Branded revenue growth to be in the mid-single digits in constant currency in 2019.

We will announce our interim results for the six months to 30 June 2019 on 9 August 2019.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.